Expanding the Role of Prescription Drug Monitoring Programs

This Viewpoint proposes an expansion of state-run prescription-drug monitoring programs to meet the need for broader pharmacovigilance given the shift to alternative payment methods that bypass traditional insurance claims.

Authors

Ashlee N. Mattingly (ORCID: https://orcid.org/0000-0001-7126-9611)

Institutions

United States Food and Drug Administration (US)
Center for Drug Evaluation and Research (US)
University of Utah (US)

Publication Details

Journal: JAMA Health Forum
Published: 2026-04-17
DOI: https://doi.org/10.1001/jamahealthforum.2026.0273
Primary Topic: Pharmacovigilance and Adverse Drug Reactions
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Expanding the Role of Prescription Drug Monitoring Programs

Ashlee N. Mattingly

Apr 17, 2026

JAMA Health Forum

Pharmacovigilance and Adverse Drug Reactions

article

Expanding the Role of Prescription Drug Monitoring Programs

Ashlee N. Mattingly

April 17, 2026article en

Abstract

JAMA Health ForumVol. 7(4)

United States Food and Drug Administration (US), Center for Drug Evaluation and Research (US), University of Utah (US)

Openalex Percentile: Top 5%

Pharmacovigilance and Adverse Drug Reactions

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Expanding the Role of Prescription Drug Monitoring Programs — Ashlee N. Mattingly · JAMA Health Forum (2026) | TGRS Research Map | TGRS